CA2777775A1 - Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes - Google Patents

Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes Download PDF

Info

Publication number
CA2777775A1
CA2777775A1 CA2777775A CA2777775A CA2777775A1 CA 2777775 A1 CA2777775 A1 CA 2777775A1 CA 2777775 A CA2777775 A CA 2777775A CA 2777775 A CA2777775 A CA 2777775A CA 2777775 A1 CA2777775 A1 CA 2777775A1
Authority
CA
Canada
Prior art keywords
phenyl
compound
spiro
piperidine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2777775A
Other languages
English (en)
French (fr)
Inventor
Chafiq Hamdouchi
Jayana Pankaj Lineswala
Pranab Maiti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43719548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2777775(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2777775A1 publication Critical patent/CA2777775A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2777775A 2009-10-15 2010-10-11 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes Abandoned CA2777775A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25183909P 2009-10-15 2009-10-15
US61/251,839 2009-10-15
US30333410P 2010-02-11 2010-02-11
US61/303,334 2010-02-11
PCT/US2010/052126 WO2011046851A1 (en) 2009-10-15 2010-10-11 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes

Publications (1)

Publication Number Publication Date
CA2777775A1 true CA2777775A1 (en) 2011-04-21

Family

ID=43719548

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2777775A Abandoned CA2777775A1 (en) 2009-10-15 2010-10-11 Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes

Country Status (25)

Country Link
US (1) US8383642B2 (https=)
EP (1) EP2488500A1 (https=)
JP (1) JP2013508279A (https=)
KR (1) KR20120051777A (https=)
CN (1) CN102574807A (https=)
AR (1) AR078522A1 (https=)
AU (1) AU2010307094A1 (https=)
BR (1) BR112012008889A2 (https=)
CA (1) CA2777775A1 (https=)
CL (1) CL2012000921A1 (https=)
CO (1) CO6531458A2 (https=)
CR (1) CR20120177A (https=)
DO (1) DOP2012000105A (https=)
EA (1) EA201270560A1 (https=)
EC (1) ECSP12011799A (https=)
IL (1) IL218344A0 (https=)
MA (1) MA33662B1 (https=)
MX (1) MX2012004420A (https=)
NZ (1) NZ598972A (https=)
PE (1) PE20121437A1 (https=)
PH (1) PH12012500705A1 (https=)
TN (1) TN2012000152A1 (https=)
TW (1) TW201124415A (https=)
WO (1) WO2011046851A1 (https=)
ZA (1) ZA201202560B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2411393T1 (sl) 2009-03-23 2014-03-31 Glenmark Pharmaceuticals S.A. Kondenzirani pirimidin-dionski derivati kot TRPA 1 modulatorji
EP2411395B1 (en) 2009-03-23 2013-05-29 Glenmark Pharmaceuticals S.A. Furopyrimidinedione derivatives as trpa1 modulators
AR078948A1 (es) * 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
CN104710381A (zh) 2009-12-25 2015-06-17 持田制药株式会社 新的3-羟基-5-芳基异噻唑衍生物
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
CN103517637B (zh) 2011-03-11 2015-12-02 洲际大品牌有限责任公司 形成多层糖食的系统和方法
RU2013152631A (ru) 2011-04-27 2015-06-10 Мотида Фармасьютикал Ко., Лтд. Новое 3-гидроксиизотиазол-1-окидное производное
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
TWI537262B (zh) * 2011-08-17 2016-06-11 美國禮來大藥廠 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators
RS55363B1 (sr) 2012-11-16 2017-03-31 Bristol Myers Squibb Co Dihidropirazolni gpr40 modulatori
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
EP3068788A1 (en) * 2013-11-14 2016-09-21 Cadila Healthcare Limited Novel heterocyclic compounds
US20150351889A1 (en) 2014-06-05 2015-12-10 Vivex Biomedical Inc. Dynamic Biometric Mesh
MX387086B (es) 2014-10-17 2025-03-19 Hyundai Pharm Co Ltd Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
US11964938B2 (en) 2018-01-08 2024-04-23 Celon Pharma S.A. 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス．エイ． スピロインデンおよびスピロインダン化合物類
CN1768041A (zh) 2003-04-04 2006-05-03 麦克公司 作为黑皮质素－4受体激动剂的酰化螺哌啶衍生物
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
CA2662242C (en) 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
BRPI0818687A2 (pt) 2007-10-26 2017-05-02 Japan Tobacco Inc composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
JP2011504499A (ja) 2007-11-21 2011-02-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ トリプターゼ阻害剤として使用するためのスピロピペリジン
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Also Published As

Publication number Publication date
MA33662B1 (fr) 2012-10-01
CL2012000921A1 (es) 2012-09-14
DOP2012000105A (es) 2013-01-31
WO2011046851A1 (en) 2011-04-21
KR20120051777A (ko) 2012-05-22
EP2488500A1 (en) 2012-08-22
IL218344A0 (en) 2012-04-30
US8383642B2 (en) 2013-02-26
AU2010307094A1 (en) 2012-04-19
NZ598972A (en) 2013-06-28
MX2012004420A (es) 2012-05-08
PH12012500705A1 (en) 2012-10-29
ZA201202560B (en) 2013-09-25
PE20121437A1 (es) 2012-10-26
BR112012008889A2 (pt) 2019-09-24
EA201270560A1 (ru) 2012-09-28
TW201124415A (en) 2011-07-16
CR20120177A (es) 2012-06-06
ECSP12011799A (es) 2012-07-31
US20110092531A1 (en) 2011-04-21
CN102574807A (zh) 2012-07-11
JP2013508279A (ja) 2013-03-07
AR078522A1 (es) 2011-11-16
TN2012000152A1 (en) 2013-12-12
CO6531458A2 (es) 2012-09-28

Similar Documents

Publication Publication Date Title
CA2777775A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
CA2781292C (en) Novel spiropiperidine compounds
KR101570624B1 (ko) 당뇨병의 치료에 유용한 신규 1,2,3,4-테트라히드로퀴놀린 유도체
NL1028624C2 (nl) Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten.
CA2209825C (en) Heterocyclic-fused pyridines
DE102007009494A1 (de) Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
DE102007042754A1 (de) Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
EP2029591A1 (de) Substituierte 4-aryl-1,4-dihydro-1,6-naphthyridine und ihre verwendung
US7816372B2 (en) 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
AU2009270363A1 (en) Compounds of estrogen-related receptor modulators and the uses thereof
EP1718653A1 (en) Glucocorticoid receptor modulator compounds and methods- utility
CA2942522C (en) 5,5-dioxo-11h-benzo[c][2,1]benzothiazepine derivatives and their use as mu-opioid receptor agonists
MXPA06009685A (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
NZ621248B2 (en) A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150811